LAMEA Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and By Country(Brazil, Mexico, Argentina, Chile, Colombia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of LAMEA) Forecasts, 2022-2030

Market Overview

The LAMEA tulathromycin market size is expected to reach USD 53.81 million by 2030, with a CAGR of 3.35%.

Tulathromycin belongs to the macrolide class of antibiotics. It is a triamilide macrolide with three charged nitrogens and a 15-membered macrolide structure (gamithromycin is also a 16-member molecule). It's made from azalide macrolides like azithromycin. It prevents bacterial protein synthesis by binding to the ribosomal 50S subunit and other macrolides. It is bacteriostatic but has bactericidal properties in vitro. Due to its positively charged molecule, it may penetrate gram-negative bacteria more quickly than other macrolide antibiotics.

Tulathromycin is used in cattle to treat BRD caused by M. haemolytica, P. multocida, and Histophilus somni (formerly Haemophilus Somnus). It is also effective in treating Mycoplasma bovis infections. When used in high-risk calves, it has also been used to prevent infections caused by these pathogens. It also treats Fusobacterium necrophorum and Porphyromonas levii-related bovine foot rot (interdigital necrobacillosis). A single dose effectively treats bovine infectious keratoconjunctivitis (Moraxella bovis).

It has been used in pigs to control and treat SRD caused by Actinobacillus pleuropneumoniae, Pneumophilus multocida, Bordetella bronchiseptica, Mycoplasma hyopneumoniae, and Haemophilus parasuis. Tulathromycin has been used to treat pulmonary abscesses in foals (off-label use).

Market Dynamics

Market Drivers

An increase in respiratory diseases will increase the demand for Tulathromycin

Bovine Respiratory Diseases (BRD) are a major concern in young and old animals. Every year, it affects 20-25% of calves, causing developmental delays for 10% of them and a death rate of up to 6%. Similarly, the increasing Swine Respiratory Diseases (SRD) in pigs can be around 20%, with a risk of sequelae of up to 40% of impacted animals and a death rate of up to 20%.

Previously, BRD and SRD had a significant monetary impact on farmers due to reduced animal development, finding and treatment expenses, mortality, and expenses associated with additional work.

Market Restraints

Generic Tulathromycin Will Limit Market Growth

The FDA in the United States approved two generic tulathromycin injections in late 2021 to treat and control specific illnesses in both cows and pigs. BRD is treated with both Macrosyn and Increxxa. Furthermore, it is used to treat SRD in pigs caused by Actinobacillus pleuropneumonia, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.

Tulathromycin is present in Macrosyn and Increxxa in the same concentration and dose structure as the supported drug item, Draxxin. The active ingredient (tulathromycin) in Macrosyn and Increxxa is the same as in the approved brand name drug product, Draxxin, first approved in 2005. Furthermore, the FDA determined that Macrosyn and Increxxa do not contain any inactive ingredients that could interfere with the active ingredient's bioavailability. In the coming years, the general interest in tulathromycin will likely be hampered by these two conventional medications.

Tulathromycin is a critical antibacterial in human medicine, and it should be handled with caution. As a result, Macrosyn and Increxxa, like Draxxin, are only available by prescription since a veterinarian's knowledge is required to identify whether tulathromycin is appropriate medication and to guide its wise use in order; to reduce the spread of antimicrobial resistance. Furthermore, tulathromycin is only approved for a single dose. The FDA does not expect these generic approvals to increase overall tulathromycin use; rather, they will provide veterinarians with options when prescribing a tulathromycin product.

Regional Analysis

The LAMEA Tulathromycin market is divided into Brazil, Argentina, Chile, Saudi Arabia, United Arab Emirates, South Africa, Iran, Turkey, Morocco, Nigeria & Rest of LAMEA, based on country.

Brazil, Mexico, Argentina, and Colombia have the largest economies in Latin America and the highest cattle and pig populations. Brazil now accounts for more than half of the regional cattle population, owing to the rising demand for dairy and meat products. The number of bovines in Brazil has expanded dramatically in recent years, and this estimate reflects the fact that more meat is being traded each year. The prevalence of BRD is significant, which expands the LAMEA tulathromycin market in these regions.

Segmental Analysis

The market for tulathromycin can be broken down into three categories based on type: greater than 99.0%, 98.0% to less than or equal to 99.0%, and 98% or less. The sub-segment of the market for tulathromycin is anticipated to hold the most significant market share throughout the projected period. Demand has increased across various industries, including Materials and Chemicals, for industrial valves of the highest possible quality. The current demand for tulathromycin is partly driven by the need to reduce the possibility of contamination. It is anticipated that the growing worry regarding the market and industry will drive the market for tulathromycin in the materials and chemicals sector.

Cattle, pigs, and other animals are the categories that make up this segment of the market for tulathromycin. Application valves for tulathromycin are among the most fundamental and essential components of the advanced technological world that we live in today. In the market for tulathromycin, it is anticipated that this market category will occupy the most significant market share.

Impact of covid-19

Recent Developments

• On Wednesday, June 1, 2022, Zoetis Inc. attended the Stifel 2022 Jaws and Paws Conference. Glenn David, Executive Vice President and Group President of International Operations, Aquaculture, BioDevices, and Pet Insurance, will represent the company and answer analyst questions.
• In February 2022, The Jiangsu Province Specialized, Special, New Little Giant Enterprise Award was bestowed upon Huiju Pharmaceutical 2021.